Administratiekantoor eTheRNA Immunotherapies
0741.658.931 · rovalta.com · 26/09/2026
Administratiekantoor eTheRNA Immunotherapies
Financial year 2024 · Closed on 31/12/2024
Overview
Identity
Source · BCE/KBOAdministratiekantoor eTheRNA Immunotherapies is a Private foundation incorporated in 2020. Its registered office is in Niel.
- Legal situation
- Normal situation
- BCE/KBO no. / VAT
- BE 0741.658.931
- Incorporation
- 16/01/2020
- Legal form
- Private foundation
- Registered office
- Galileilaan 19
2845 Niel · FlandreSee on map - Latest accounts
- 31/12/2024
Financials
Source · NBB, 5 filingsTrend over 5 financial years
| 2024 | 2023 | 2022 | 2021 | 2020 | |||||
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Gross margin | -85,1 € | -526% | -13,6 € | +94.8% | -264 € | – | -1,8 k € | ||
| EBITDA | -139,1 € | -17.3% | -118,6 € | +67.5% | -365 € | – | -1,8 k € | ||
| Operating result | -139,1 € | -17.3% | -118,6 € | +67.5% | -365 € | – | -1,8 k € | ||
| Net result | -139,1 € | -17.3% | -118,6 € | +67.5% | -365 € | – | -1,8 k € | ||
| Balance sheet | |||||||||
| Equity | -2,5 k € | -6.0% | -2,3 k € | -5.4% | -2,2 k € | -19.8% | -1,8 k € | 0.0% | -1,8 k € |
| Debts | 2,5 k € | +6.0% | 2,3 k € | +5.4% | 2,2 k € | +19.8% | 1,8 k € | 0.0% | 1,8 k € |
Board of directors
Source · NBB, accounts to 31/12/20241 active · 2 ended
Active mandates
Ended mandates
Other companies at this address
Galileilaan 19 2845 Niel| Company | CBE no. |
|---|---|
ETHERNA IMMUNOTHERAPIES● Active | 0502.703.389 |
Financials
Full financial information
Source · NBB| 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|
| Type of account | Micro model | Abridged model | Micro model | Micro model | Micro model |
| Start of the financial year | 01/01/2024 | 01/01/2023 | 01/01/2022 | 01/01/2021 | 15/01/2020 |
| Closing of the financial year | 31/12/2024 | 31/12/2023 | 31/12/2022 | 31/12/2021 | 31/12/2020 |
| Length of the financial year | 12 months | 12 months | 12 months | 12 months | 12 months |
| Filing date | 28/07/2025 | 16/07/2024 | 29/06/2023 | 15/06/2022 | 15/06/2022 |
| General meeting | 30/06/2025 | 17/06/2024 | 15/06/2023 | 10/05/2022 | 30/06/2021 |
| Currency of the financial year | EUR | EUR | EUR | EUR | EUR |
| NBB quality label | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls |
Financial ratios
Source · NBBLooking for more information about this company?
Try for freeAnnual accounts filings
Source · NBB, 5 filingsValuation
Indicative valuation
The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.
Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.
Directors & structure
Board of directors
Source · NBB, accounts to 31/12/20241 active · 2 ended
Active mandates
Ended mandates
Ownership and network
Looking for more information about this company?
Try for freePublications
Similar companies
Similar companies
A company's peers, by sector and size, are included in the Business plan.
See the Business planTimeline
Timeline
- 2024Annual accounts 2024-139,1 €↓
- 2023Annual accounts 2023-118,6 €↑
- 2022Annual accounts 2022-365 €↑
- 2021Annual accounts 2021
- 2020Annual accounts 2020-1,8 k €
- 16/01/2020IncorporationPrivate foundation